PT - JOURNAL ARTICLE AU - Heiss, Rafael AU - Wagner, Alexandra AU - Tan, Lina AU - Schmidt, Sandy AU - Regensburger, Adrian P. AU - Ewert, Franziska AU - Mammadova, Dilbar AU - Buehler, Adrian AU - Vogel-Claussen, Jens AU - Voskrebenzev, Andreas AU - Rauh, Manfred AU - Rompel, Oliver AU - Nagel, Armin M. AU - Lévy, Simon AU - Bickelhaupt, Sebastian AU - May, Matthias S. AU - Uder, Michael AU - Metzler, Markus AU - Trollmann, Regina AU - Woelfle, Joachim AU - Knieling, Ferdinand TI - Persisting pulmonary dysfunction in pediatric post-acute Covid-19 AID - 10.1101/2022.02.21.22270909 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.21.22270909 4099 - http://medrxiv.org/content/early/2022/02/22/2022.02.21.22270909.short 4100 - http://medrxiv.org/content/early/2022/02/22/2022.02.21.22270909.full AB - The frequency and extent of persistent sequelae in children and adolescents after infection with SARS-CoV-2 still needs to be comprehensively determined. In this cross-sectional clinical trial, we used non-invasive, label-free morphologic and free-breathing phase-resolved functional low-field magnetic resonance imaging (LF-MRI) to identify pulmonary changes in children and adolescents from 5 to <18 years after previously PCR-confirmed SARS-CoV-2 infection. While morphological pathologies were less frequent in children, functional LF-MRI visualized widespread ventilation, perfusion and combined ventilation/perfusion defects compared to healthy controls. The loss of functional lung parenchyma was more pronounced in long Covid than recovered patients. While pulmonary dysfunction was persistent even month after primary infection, LF-MRI demonstrated high capability to visualize and detect these changes in children and adolescents. (Clinicaltrials.org ID NCT04990531)Competing Interest StatementR.H., M.U. and M.M. are part of the speakers bureau of the Siemens Healthcare GmbH. The authors have no further affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript. F.K. received speaker honorary from Siemens Healthcare GmbH. All other authors declare no conflict of interest.Clinical TrialNCT04990531Funding StatementJunior project (J089) and Clinician Scientist Program (CSP) from the Interdisciplinary Center for Clinical Research (IZKF) at the Friedrich-Alexander-Universitaet (FAU) Erlangen-Nuernberg for A.P.R. This work received funding from the Bayerisches Staatsministerium fuer Wissenschaft und Kunst.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Friedrich-Alexander-University Erlangen-Nuremberg gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.